Hypertension is considered as the most common risk factor for cardiovascular diseases, also
is regarded as a leading cause of the mortality and morbidity worldwide. The mechanisms …

Background—Alterations in endothelial function may contribute to increased susceptibility of
black Americans to cardiovascular disease. The ability to pharmacologically reverse …

Although its clinical use in Europe dates almost 10 years, nebivolol is a β-blocker that has
been only recently introduced in the US market. Like carvedilol, nebivolol belongs to the …

Background—Vascular damage caused by cerebral ischemia leads to edema, hemorrhage
formation, and worsened outcomes in ischemic stroke patients. Therapeutic interventions …

Background: Activation of the sympathetic nervous system (SNS) has been linked to
hypertension. Beta-blockers, which decrease SNS activation via β-adrenergic receptor …

Nebivolol is a highly selective β 1-adrenergic receptor antagonist with a pharmacologic
profile that differs from those of other drugs in its class. In addition to cardioselectivity …

A large body of evidence indicates that patients with essential hypertension are
characterized by endothelial dysfunction mediated by an impaired NO availability secondary …

Objectives Endothelial dysfunction is a new pathway in cardiovascular disease (CVD)
development. Psychosocial factors have been little studied in relation to endothelial function …

Pharmacological compounds that release nitric oxide (NO) have been useful tools for
evaluating the broad role of NO in physiology and therapeutics. NO deficiency has been …

Nebivolol is a β1-receptor antagonist with vasodilator and antioxidant properties. Because
the vascular NADPH oxidase is an important superoxide source, we studied the effect of …